CL2011000361A1 - Uso de dabigatran para preparar un medicamento util para medicacion secundaria en la cateterizacion cardiaca intervencionista percutanea realizada en conjunto con la implantacion de un stent. - Google Patents

Uso de dabigatran para preparar un medicamento util para medicacion secundaria en la cateterizacion cardiaca intervencionista percutanea realizada en conjunto con la implantacion de un stent.

Info

Publication number
CL2011000361A1
CL2011000361A1 CL2011000361A CL2011000361A CL2011000361A1 CL 2011000361 A1 CL2011000361 A1 CL 2011000361A1 CL 2011000361 A CL2011000361 A CL 2011000361A CL 2011000361 A CL2011000361 A CL 2011000361A CL 2011000361 A1 CL2011000361 A1 CL 2011000361A1
Authority
CL
Chile
Prior art keywords
medication
dabigatran
stent
implantation
prepare
Prior art date
Application number
CL2011000361A
Other languages
English (en)
Spanish (es)
Inventor
Paul A Reilly
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41258283&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011000361(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2011000361A1 publication Critical patent/CL2011000361A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
CL2011000361A 2008-08-19 2011-02-18 Uso de dabigatran para preparar un medicamento util para medicacion secundaria en la cateterizacion cardiaca intervencionista percutanea realizada en conjunto con la implantacion de un stent. CL2011000361A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9001808P 2008-08-19 2008-08-19

Publications (1)

Publication Number Publication Date
CL2011000361A1 true CL2011000361A1 (es) 2011-06-17

Family

ID=41258283

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000361A CL2011000361A1 (es) 2008-08-19 2011-02-18 Uso de dabigatran para preparar un medicamento util para medicacion secundaria en la cateterizacion cardiaca intervencionista percutanea realizada en conjunto con la implantacion de un stent.

Country Status (19)

Country Link
US (1) US20110301201A1 (enExample)
EP (1) EP2328580A1 (enExample)
JP (1) JP2012500245A (enExample)
KR (1) KR20110044230A (enExample)
CN (1) CN102123707A (enExample)
AR (1) AR073077A1 (enExample)
AU (1) AU2009284217A1 (enExample)
BR (1) BRPI0917507A2 (enExample)
CA (1) CA2734794A1 (enExample)
CL (1) CL2011000361A1 (enExample)
CO (1) CO6290686A2 (enExample)
EA (1) EA201100358A1 (enExample)
EC (1) ECSP11010825A (enExample)
IL (1) IL210005A0 (enExample)
MA (1) MA32563B1 (enExample)
MX (1) MX2011001612A (enExample)
NZ (1) NZ591108A (enExample)
TW (1) TW201022235A (enExample)
WO (1) WO2010020602A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2358368A1 (en) 2008-11-11 2011-08-24 Boehringer Ingelheim International GmbH Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
CA2791561A1 (en) * 2010-03-01 2011-09-09 Ratiopharm Gmbh Dabigatran etexilate-containing oral pharmaceutical composition
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
CN102391250B (zh) * 2011-08-29 2013-06-19 石药集团欧意药业有限公司 一种达比加群酯化合物、制备方法及其药物组合物
CN102558153A (zh) * 2012-02-08 2012-07-11 北京阜康仁生物制药科技有限公司 达比加群酯的新药用盐及其制备方法
CN103420984B (zh) * 2012-05-24 2015-07-08 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103420982B (zh) * 2012-05-24 2015-07-08 天津药物研究院 达比加群酯衍生物及其制备方法和用途
CN103420994B (zh) * 2012-05-24 2016-04-06 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103420985B (zh) * 2012-05-24 2015-09-23 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103524559B (zh) * 2012-07-05 2016-09-28 西藏海思科药业集团股份有限公司 多取代4-甲氨基苯甲脒的酯衍生物及其制备方法和用途
CN103539779B (zh) * 2012-07-13 2016-12-21 四川海思科制药有限公司 一种达比加群酯的羟基取代苯磺酸盐及其制备方法和用途
IN2015DN02601A (enExample) * 2012-09-28 2015-09-18 Ranbaxy Lab Ltd
US9399616B2 (en) 2012-10-22 2016-07-26 Boehringer Ingelheim International Gmbh Process for the manufacture of 4-aminobenzoamidine dihydrochloride
WO2014149139A2 (en) 2013-03-15 2014-09-25 Verseon, Inc. Halogenopyrazoles as inhibitors of thrombin
DK2968297T3 (en) 2013-03-15 2019-01-07 Verseon Inc MULTI-SUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS
JP2017528486A (ja) 2014-09-17 2017-09-28 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
ES2931460T3 (es) 2015-02-27 2022-12-29 Verseon Int Corporation Compuestos de pirazol sustituido como inhibidores de serina proteasa
IL280078B2 (en) 2018-07-13 2024-04-01 Verseon Int Corporation Thrombin inhibitors, formulations, and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1485094B2 (de) * 2002-03-07 2020-03-25 Boehringer Ingelheim International GmbH Oral zu applizierende darreichungsform für 3- [(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester oder dessen salze
JP2008517974A (ja) * 2004-10-25 2008-05-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗血栓薬と併用しての血栓塞栓性疾患の治療および予防のためのジピリダモールの使用
CA2657270A1 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New paediatric indications for direct thrombin inhibitors
JP2009543842A (ja) * 2006-07-17 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓血管分野における直接トロンビン阻害薬のための新規適応
US20100087488A1 (en) * 2006-10-10 2010-04-08 Boehringer Ingelheim International Gmgh Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester

Also Published As

Publication number Publication date
KR20110044230A (ko) 2011-04-28
AU2009284217A1 (en) 2010-02-25
AR073077A1 (es) 2010-10-13
JP2012500245A (ja) 2012-01-05
MA32563B1 (fr) 2011-08-01
TW201022235A (en) 2010-06-16
IL210005A0 (en) 2011-02-28
ECSP11010825A (es) 2011-03-31
WO2010020602A1 (en) 2010-02-25
EA201100358A1 (ru) 2011-10-31
MX2011001612A (es) 2011-03-04
BRPI0917507A2 (pt) 2015-11-17
EP2328580A1 (en) 2011-06-08
NZ591108A (en) 2012-11-30
CA2734794A1 (en) 2010-02-25
CN102123707A (zh) 2011-07-13
US20110301201A1 (en) 2011-12-08
CO6290686A2 (es) 2011-06-20

Similar Documents

Publication Publication Date Title
CO6290686A2 (es) Dabigatrán para la cateterización cardiaca intervencionista percutánea
CO6491052A2 (es) Compuestos espirociclicos que contienen notrogeno y su uso medicinal
DOP2015000051A (es) Formulaciones acuosas estables de adalimumab
ECSP14009999A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
CR20120469A (es) Compuesto de pirazol-4-il-heterociclil-carboxamida y métodos de uso
CO6620050A2 (es) Derivados de aminopirimidina como moduladores de la lrrk2
DOP2014000203A (es) Compuestos de heterociclilo
MX394360B (es) Inhibidores de jak2 y alk2 y metodos para su uso.
UY31124A1 (es) Derivados de oxiadazol y su uso como potenciadores del receptor metabotropico de glutamato - 842
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
BRPI0916072A2 (pt) "uso de uma formulação, formulação farmacêutica, usos de um anticorpo 2h7 humanizado, método, método para aumentar a biodisponibilidade de um anticorpo e método de diálise in vitro"
CR20140318A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
UY35087A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
UA105827C2 (uk) Терапевтична комбінація теоброміну і антигістаміну, який діє на н1-рецептор
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
UA111324C2 (uk) Агент для профілактики або зменшення пігментації
CL2009000257A1 (es) Uso de imidazolinas 1,3 sustituidas y de sus sales fisiologicamente compatibles para el tratamiento del sindrome metabolico.
WO2013025751A3 (en) Urethral catheter tension holding and movement stabilizing devices
AR058047A1 (es) Administracion de inhibidores de dipeptidil peptidasa
ECSP078037A (es) Formulaciones farmacéuticas de liberación inmediata y con una carga de droga elevada de (4-clorofenil)[4-(4-piridilmetil)ftalazin-1-ilo] micronizado, y sus sales
UA118008C2 (uk) Спосіб синтезу (2е)-3-(3,4-диметоксифеніл)проп-2-еннітрилу та застосування в синтезі івабрадину та його адитивних солей з фармацевтично прийнятною кислотою
AR082021A1 (es) Semuloparina para uso como un tratamiento antitrombotico en cirugia de reemplazamiento de cadera con disminucion de la incidencia de hemorragias clinicamente relevantes y hemorragias mayores
WO2011161465A3 (en) Composition for treatment of skin
UA57852U (ru) Способ лечения рецидивных форм аллергодерматозов у больных c наличием вторичных иммунодефицитных состояний
Li-Ying et al. Calmodulin kinase 2 activation is required for the maintenance of basal activity of L-type Ca [2+] channels in guinea-pig ventricular myocytes